OraSure Technologies (NASDAQ:OSUR) Issues Earnings Results

Key Points

• OraSure Technologies reported a quarterly loss of ($0.23) earnings per share (EPS), missing analysts' expectations of ($0.15) by ($0.08).
• The company's stock price remained flat at $3.12, with a market capitalization of $233.38 million and a price-to-earnings ratio of -7.43.
• Several institutional investors, including Amundi and Envestnet Asset Management, have recently increased their stakes in OraSure Technologies, with institutional ownership now at 93.50%.

OraSure Technologies (NASDAQ:OSUR - Get Free Report) posted its quarterly earnings results on Tuesday. The medical instruments supplier reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.08), Zacks reports. OraSure Technologies had a negative net margin of 36.84% and a negative return on equity of 10.81%. The business had revenue of $31.24 million during the quarter, compared to the consensus estimate of $30.52 million. OraSure Technologies updated its Q3 2025 guidance to EPS.

OraSure Technologies Stock Up 1.5%

Shares of NASDAQ OSUR traded up $0.04 during trading hours on Friday, hitting $2.78. 547,602 shares of the stock were exchanged, compared to its average volume of 762,809. OraSure Technologies has a 12 month low of $2.36 and a 12 month high of $4.61. The company has a market cap of $203.33 million, a PE ratio of -4.15 and a beta of 0.27. The firm has a fifty day moving average price of $3.04 and a 200-day moving average price of $3.20.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC increased its stake in OraSure Technologies by 6.4% during the 2nd quarter. Geode Capital Management LLC now owns 1,869,868 shares of the medical instruments supplier's stock valued at $5,611,000 after purchasing an additional 112,851 shares in the last quarter. Envestnet Asset Management Inc. increased its stake in OraSure Technologies by 32.7% during the 2nd quarter. Envestnet Asset Management Inc. now owns 33,018 shares of the medical instruments supplier's stock valued at $99,000 after purchasing an additional 8,133 shares in the last quarter. Empowered Funds LLC increased its stake in OraSure Technologies by 7.2% during the 1st quarter. Empowered Funds LLC now owns 405,216 shares of the medical instruments supplier's stock valued at $1,366,000 after purchasing an additional 27,310 shares in the last quarter. NewEdge Advisors LLC increased its stake in OraSure Technologies by 32,595.9% during the 1st quarter. NewEdge Advisors LLC now owns 47,736 shares of the medical instruments supplier's stock valued at $161,000 after purchasing an additional 47,590 shares in the last quarter. Finally, AQR Capital Management LLC increased its stake in OraSure Technologies by 48.3% during the 1st quarter. AQR Capital Management LLC now owns 1,041,875 shares of the medical instruments supplier's stock valued at $3,511,000 after purchasing an additional 339,493 shares in the last quarter. Institutional investors and hedge funds own 93.50% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on OSUR. Wall Street Zen upgraded shares of OraSure Technologies from a "sell" rating to a "hold" rating in a report on Saturday, May 17th. Evercore ISI reiterated an "in-line" rating and set a $3.00 price objective on shares of OraSure Technologies in a research note on Monday, May 19th.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.